IMMUNOME v4 Discovery Array

Product Number 30008

Pricing


CodeProduct Description
30008 AIMMUNOME™ v4 Discovery Array Service
30008IMMUNOME™ v4 Discovery Array Kit

Description

IMMUNOME™ v4 Discovery Array is a protein array which utilises the patented Sengenics KREX™ functional proteomics technology. All proteins on the IMMUNOME™ v4 Discovery Array are correctly folded and functional as they are expressed as fusion proteins with biotin carboxyl carrier protein (BCCP) which acts as a folding marker and solubility enhancer. The IMMUNOME™ v4 Discovery Array contains 1600+ full-length human proteins from biologically significant protein families including kinases, signalling molecules, cytokines, interleukins, chemokines and cancer antigens. The arrays are coated with a proprietary surface which preserves protein folding and inhibits binding of non-specific proteins.

    1. Discovery of autoantibody biomarkers for diagnostics
    2. Discovery of autoantibody biomarkers of risk of adverse drug reactions
    3. Discovery of autoantibody-based therapeutic and prophylactic biologics
    4. Determining effect of citrullination on autoantibody interactions
    5. Functional assays for any protein or any interacting biomolecule


Specifications

Product name:

IMMUNOME™ v4 Discovery Array

Minimum Order : 30 slides

Slide Type: Streptavidin-coated glass slide

Species: Human

Storage: Store for up to 12 months at -20°c

Delivery lead time: 4 weeks

DOWNLOADS

Resources to access our technology

FAQs

Your technical questions – answered

SOLUTIONS

One technology – endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2019 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X